Earlier clinical scientific studies of CagriSema observed that it aided people obtain appreciably greater weight loss than semaglutide (Wegovy) did. Even if Lilly's Zepbound/Mounjaro topples Wegovy, It is attainable that CagriSema could enter the marketplace at the correct time for Novo Nordisk to keep its Total Management within the weight problem